Articles tagged with Drug Therapy
A new study published in Alzheimer's & Dementia found that cholinesterase inhibitors (ChEIs) may slow down cognitive decline in dementia with Lewy bodies over five years. ChEIs were also associated with a reduced risk of death in the first year after diagnosis.
Researchers at Åbo Akademi University have discovered a crucial protein, TLNRD1, that helps maintain blood vessel stability in the brain. The study highlights the potential for targeted molecular therapies to improve patient outcomes in CCM disease.
Elinzanetant, a selective neurokinin-1,3 receptor antagonist, demonstrated significant reductions in vasomotor symptoms frequency and severity vs placebo in postmenopausal individuals with moderate to severe VMS. The treatment also improved sleep disturbances and menopause-related quality of life, with a favorable safety profile.
Researchers developed tumor cell-coated carbon nanohorns to deliver paclitaxel to colon cancer, exhibiting high accumulation at tumors and strong chemotherapeutic effects. The treatment also demonstrated a robust photothermal effect and immune responses, effectively destroying tumors.
Researchers at the University of Virginia School of Engineering and Applied Science have designed a drug-carrying molecule that can slip past the lung's natural defenses. The nanocarrier, called PEG-BB, is shaped like a bottlebrush and mimics the properties of mucus, allowing it to move quickly through the airway.
Researchers developed a treatment approach using lipid nanoparticles to deliver mRNA therapy for MSUD, extending survival and reducing serum leucine levels. The study also identified a novel AAV variant with desirable biodistribution properties for targeting peripheral organs.
A clinical study confirmed the safety of aceneuramic acid in treating distal myopathy with rimmed vacuoles (GNE myopathy), a rare disease causing progressive muscle weakness. The treatment, developed for an ultra-orphan drug, showed efficacy and was approved by Japan's Ministry of Health, Labour and Welfare.
A new study published in Nature Medicine shows that precision therapy can improve survival for men with metastatic castration-resistant prostate cancer. The treatment, which involves analyzing the genetic profile of the tumor, has been shown to be more effective than chemotherapy in patients whose tumors have specific mutations.
A new study by Korea University College of Medicine shows that direct-acting antivirals significantly reduce liver-related clinical outcomes and lower the risk of disease progression to cancer or cirrhosis, increasing life expectancy for patients with Hepatitis C. The treatment approach has a high effectiveness rate of 90%.
A new study by UCLA investigators found that Manuka honey contains compounds that can help reduce tumor growth in preclinical models. The research suggests that Manuka honey could potentially be developed into a natural supplement or standalone treatment for ER-positive breast cancer, which accounts for most breast cancer cases.
A wearable sensor supported by machine learning models can continuously monitor and quantify FOG episodes, providing an accurate picture of a patient's condition. This technology has the potential to support the development of new treatments and improve the lives of people with Parkinson's disease.
The International Space Station National Laboratory is collaborating with NASA to fund up to $4 million in research addressing significant diseases like cancer, cardiovascular disease, and neurodegenerative disease. The joint solicitation aims to leverage microgravity to improve existing or develop new technologies for health problems ...
Texas A&M researchers are investigating the use of extracellular vesicles to deliver immune-suppressing proteins, potentially reducing the immune system's attack on insulin-producing beta-cells. The goal is to develop a novel treatment for type 1 diabetes, which currently has only lifelong insulin therapy as an approved option.
A team of researchers, led by Jason Shoemaker, are studying the effects of hormones on the immune system's response to the flu. Their goal is to develop targeted therapies based on a person's sex or hormone levels. The study aims to identify the molecules or pathways that affect the cells and begin to develop personalized treatments.
Researchers have identified new immune checkpoints, including T cell immunoreceptor with Ig and ITIM domains (TIGIT), T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), and lymphocyte activation gene-3 (LAG-3), which help tumors evade the immune system.
UMass Amherst researchers have identified the 'quality control' regulator for protein folding, a crucial process that ensures essential cellular functions. The discovery of this regulator, Sep15, could lead to new treatments targeting misfolded proteins associated with diseases like Alzheimer's and cystic fibrosis.
Pregnant women exposed to buprenorphine combined with naloxone had similar or more favorable outcomes compared to those exposed to buprenorphine alone. This suggests that both formulations are safe treatment options for opioid use disorder during pregnancy.
Researchers from Tokyo University of Science have developed an efficient method to synthesize eutyscoparol A and violaceoid C, two compounds with potential therapeutic properties. The new approach improves yields and simplifies synthesis steps, enabling further research into their pharmacological effects.
Researchers from POSTECH and KRICT created a 3D artificial lung using bioprinting technology, closely mimicking the human respiratory tract. This model allows for accurate testing of COVID-19 drugs and development of therapeutic treatments, potentially shortening the drug development process to under 5 years.
A trial at UT Health San Antonio found that Sacituzumab Govitecan was well-tolerated and showed signs of effectiveness for patients with breast cancer who had progressed to brain tumors. The drug has been shown to deliver a topoisomerase inhibitor into tumors, providing promising clinical signals of efficacy.
Researchers at Michigan State University characterized how fungi restructure their cell walls to thwart current antifungal medications. The study found that fungi enhance their survival odds by making specific changes to the structure and organization of the components in their cell walls, rendering existing drugs ineffective.
A new editorial published in Aging suggests that starting targeted cancer therapies with high concentrations may slow down the selection for resistance. This approach could potentially be used as a preemptive measure to minimize the development of resistance.
A study found that increased expression of human carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) on immune cells is associated with treatment-resistant melanoma. CEACAM1 is now considered a potential therapeutic target for patients with resistant tumors.
Researchers analyzed data from 63,700 patients in five clinical trials to understand the impact of clonal hematopoiesis of indeterminate potential (CHIP) on heart disease. They found that patients with CHIP had a 30% higher risk of initial heart attacks but not recurrent events.
Researchers question the effectiveness of new amyloid immunotherapy drugs in reducing Alzheimer's disease impact, citing limited eligibility and high costs. The drugs showed small effect sizes that may not outweigh the risk of adverse events.
A survey study estimates that 15.6 million US adults consume at least one potentially hepatotoxic botanical product within the past 30 days. Turmeric is the most commonly reported botanical, followed by green tea, ashwagandha, Garcinia cambogia, red yeast rice, and black cohosh products.
A new study found that subclinical hypothyroidism diagnosed before 21 weeks of pregnancy is associated with higher rates of overt hypothyroidism or thyroid replacement therapy within 5 years after delivery. Women with high TSH values and elevated TPO antibodies were at increased risk.
Researchers at H. Lee Moffitt Cancer Center & Research Institute propose a unified framework for understanding antifragility in complex systems, including cancer. The study suggests that applying principles of antifragility could lead to dynamic and responsive cancer therapies.
A new study from Michigan Medicine suggests that inhibiting the SWI/SNF epigenetic complex can therapeutically target oncogenic transcription factors. The research, led by Arul Chinnaiyan, builds on previous work to find genetic vulnerabilities in transcription factor-driven cancers.
The PD GENEration study has found that 13% of participants have a genetic form of Parkinson's disease, significantly higher than previous estimates. The study, which reached its goal of 15,000 participants ahead of schedule, provides insights into the genetics of the disease and its potential for precision medicine.
Researchers found that a cancer drug can restore phagocytosis, a process crucial for brain health, in individuals with Rett syndrome by targeting microglia. The study highlights the potential therapeutic target of microglia in neurological conditions and may lead to new treatments.
A recent study published in Scientific Reports found that blocking connexin 43 (Cx43) channels with the compound INI-0602 improved MS symptoms in an animal model by regulating immune processes and reducing inflammation. The findings suggest a potential therapeutic strategy for chronic MS treatment.
The E1910 trial demonstrated a significant survival advantage with blinatumomab immunotherapy, improving overall and relapse-free survival in patients with BCR::ABL1-negative B-cell precursor acute lymphoblastic leukemia. This finding contributed to the recent FDA approval of blinatumomab for these patients.
A recent study found that 'gene misbehaviour' is a common phenomenon in the healthy human population, with over half of inactive genes showing misexpression. The researchers used advanced techniques to analyze blood samples from 4,568 healthy individuals and identified mechanisms behind these gene activity errors.
Researchers developed a triple-adeno-associated virus vector system to deliver full-length dystrophin protein into muscles, restoring muscle health and strength in mice models with Duchenne muscular dystrophy. The approach has shown promise for treating patients with the genetic disorder.
A new study published in Nucleic Acid Therapeutics found that siRNA reduces huntingtin mRNA levels in the cytoplasm but not in the nucleus of mouse brains, suggesting a limitation in its effectiveness for treating Huntington's disease. The research highlights the importance of understanding the structure and function of nuclear RNA to ...
Scientists at Trinity College Dublin have identified a key biological pathway, the JAK/STAT pathway, that RSV suppresses and prevents immune system igniters from activating. This discovery provides a promising new target for therapeutic immune restoration and could lead to significant impact in treating RSV infections.
Researchers have generated the largest collection of patient-derived mouse models to study pseudomyxoma peritonei, a rare cancer with few treatment options. They found that BRAF inhibitor encorafenib significantly reduced tumor growth and prolonged survival in mice.
Researchers found that subretinal adeno-associated virus 8 injections trigger proinflammatory T-cell responses, but co-injection of immunodominant peptides can modulate the immune system. This study suggests a new approach to AAV gene therapy for retinal diseases.
The new guidelines from the Surgical Infection Society offer updated recommendations for antimicrobial agent selection, source control, and treatment of specific pathogens. These evidence-based guidelines aim to improve clinical outcomes and reduce mortality rates from intra-abdominal infections globally.
A new study finds that psilocybin temporarily desynchronizes the default mode network in the brain, creating a psychedelic experience. The study provides a neurobiological explanation for the drug's effects and lays groundwork for its potential use as a therapy for mental illnesses.
Researchers created a new cell model to study the effects of senescence on lung fibroblasts. Senescent alveolar epithelial cells triggered fibrotic activation in lung fibroblasts, which was attenuated by senolytic therapy.
Researchers from Radboud University Medical Center discuss the potential of using early on-treatment circulating tumor DNA measurements as a response assessment for metastatic castration-resistant prostate cancer. The detection of ctDNA at baseline and 4-weeks after treatment initiation can predict response durability to first-line ARPIs.
Researchers at Mainz University have identified aniquinazolin B, a natural substance from the marine fungus Aspergillus nidulans, which stimulates opioid receptors and could potentially replace opioids in the long term. The compound shows promising results with fewer undesirable reactions compared to opioids.
Researchers developed a library of 27 polymers to improve RNA drug delivery, using design-of-experiment approach and statistical analysis. The study improves quality, efficiency, and precision of RNA drugs with optimized polymer nanoparticles.
A study published in Nature Medicine found that off-the-shelf wearable trackers can monitor the response to two treatments for atrial fibrillation and heart failure. The devices provided clinically useful information similar to in-person hospital assessments, with a neural network helping to analyze missing data.
The study compared FDG-PET/CT and CT for evaluating treatment response in unresectable malignant pleural mesothelioma patients. The results showed that both imaging modalities provided accurate findings for tumor response evaluation, with high concordance between the two methods.
Researchers found that autologous bone marrow aspirate concentrate (BMAC) and adipose-derived stromal vascular fraction (ADSVF) have distinct cellular compositions and protein profiles. The study's findings challenge the marketing of these therapies as interchangeable and highlight the need for standardized cell therapies.
A new study analyzed clozapine prescription patterns in patients with first-episode psychosis, finding that approximately 20-30% do not respond to conventional treatments. The use of clozapine can significantly reduce psychotic symptoms and improve quality of life for these patients.
A new potential therapy for depressed patients with bipolar disorder has emerged, significantly shortening treatment time from four to six weeks. Accelerated intermittent theta burst stimulation (aiTBS) reduced treatment to just five days, yielding substantial decreases in depressive symptoms.
Researchers describe redundant innate immune pathways triggered by AAV vectors, including sensing of viral genome and cytoplasmic DNA sensors. The study highlights the need to understand complex biologic mechanisms underlying adverse reactions to AAV vectors in human gene therapy trials.
Researchers found increased liver oxidative stress and impaired antioxidant defenses in a DS murine model. The study suggests potential therapeutic strategies targeting oxidative stress and lipid metabolism to prevent or mitigate liver-related complications.
Researchers at Linköping University created a tool to predict risk of persistent side effects in breast cancer patients treated with taxane drugs. The model uses genetic characteristics to forecast the risk of nerve damage, which can be used to adapt treatment and improve patient outcomes.
A new framework for diagnosing and managing obesity in adults proposes modernizing obesity diagnosis to take account of all the latest developments in the field. The authors recognize that BMI alone is insufficient as a diagnostic criterion and that body fat distribution has a substantial effect on health.
Scientists have mapped over 5,000 genetic variants in the 'tumour protection' gene BAP1 that significantly increase cancer risk. These variants can be used to develop new treatments, including IGF-1 inhibitors, to slow down or prevent cancer progression.
Researchers have discovered a new diagnostic method for PSP by analyzing protein biomarkers in spinal fluid, which could lead to earlier diagnosis and targeted therapies. The high-throughput technology allows for the measurement of thousands of proteins in a tiny drop of fluid, providing a promising solution for identifying the condition.
Researchers discovered that dexamethasone works in patients with severe COVID-19 by influencing impaired inflammatory response through specific immune cells. A predictive tool using single-cell analysis can identify early responders to treatment, offering hope for targeted therapy development.
Pharmacogenomics (PGx) testing can predict how patients will respond to systemic therapies, enabling personalized treatment plans and optimizing medication dosages. A specific gene variant, HSD3B1, has been linked to castration-resistant prostate cancer progression.
Researchers describe a new concept for an immune response against cancer and aging using senescent cell-derived vaccines. The vaccines aim to stimulate the immune system against cancer cells and slow down or reverse aging-related diseases.
A team of researchers has created a new approach to deliver drugs precisely to surgically repaired tendons using nanoparticles, reducing scar tissue formation and improving function. The treatment targets the Acp5 gene, which is highly expressed at the injury site, and delivers medication directly to the healing tendon.